Medilief Biosciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 13 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -29.90%
- Profit Growth -15.46%
- Ebitda -17.12%
- Net Worth 23.21%
- Total Assets -20.30%
About Medilief Biosciences
Medilief Biosciences Private Limited (MBPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 October 2011 and has a history of 13 years and four months. Its registered office is in Delhi, India.
The Corporate was formerly known as Onconep Healthcare Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vikas Goel and Nandini Goel serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74900DL2011PTC226072
- Company No.
226072
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Oct 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Medilief Biosciences Private Limited offer?
Medilief Biosciences Private Limited offers a wide range of products and services, including Cardiac Drugs, Adenosine Monophosphate Injection.
Who are the key members and board of directors at Medilief Biosciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikas Goel  | Director | 15-Jul-2013 | Current |
| Nandini Goel | Director | 11-Oct-2011 | Current |
Financial Performance of Medilief Biosciences.
Medilief Biosciences Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 29.9% decrease. The company also saw a substantial fall in profitability, with a 15.46% decrease in profit. The company's net worth Soared by an impressive increase of 23.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medilief Biosciences?
In 2021, Medilief Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Medilief Biosciences?
Unlock and access historical data on people associated with Medilief Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medilief Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medilief Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
